Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 04-2013 | 01-2013 | 10-2012 | 07-2012 | 04-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 6,674 | 8,478 | 3,313 | 4,862 | 5,867 |
| Receivables | 117 | 271 | 666 | 733 | 1,738 |
| Inventories | 0 | 0 | 305 | 421 | 456 |
| Other current assets | 0 | 0 | 0 | 0 | 4 |
| TOTAL | $6,945 | $8,964 | $4,425 | $6,123 | $8,191 |
| Non-Current Assets | |||||
| PPE Net | 762 | 857 | 959 | 1,049 | 1,546 |
| Other Non-Current Assets | 444 | 444 | 444 | 444 | 265 |
| TOTAL | $1,206 | $1,301 | $1,403 | $1,493 | $1,811 |
| Total Assets | $8,151 | $10,265 | $5,828 | $7,616 | $10,002 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 799 | 652 | 744 | 650 | 1,140 |
| Accrued Expenses | 491 | 590 | 799 | 694 | 692 |
| TOTAL | $1,315 | $1,267 | $1,568 | $1,369 | $1,857 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 4 | 10 | 17 | 23 | 29 |
| TOTAL | $4 | $10 | $17 | $23 | $29 |
| Total Liabilities | $1,319 | $1,277 | $1,585 | $1,392 | $1,886 |
| Shareholders' Equity | |||||
| Common Shares | 102,393 | 102,393 | 0 | 0 | 0 |
| Retained earnings | -116,331 | -114,107 | -118,776 | -116,699 | -114,844 |
| Other shareholders' equity | 11,733 | 13,151 | 13,257 | 13,203 | 13,270 |
| TOTAL | $6,832 | $8,988 | $4,243 | $6,224 | $8,116 |
| Total Liabilities And Equity | $8,151 | $10,265 | $5,828 | $7,616 | $10,002 |